Good News for Stem Cell Transplants
Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment.
Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment.
Health care spending in America reached a stunning $3.5 trillion in 2017, but that’s just the beginning. According to Centers for Medicare and Medicaid Services, that figure is projected to shoot up to $6…
Eli Lilly shares made a handy gain on Tuesday after the firm announced results from its late-stage study for the treatment of moderate to severe plaque psoriasis.
Deciphera Pharma shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Alzheimer’s disease and other forms of dementia are a growing worldwide health problem, affecting some 50 million people around the globe, and it’s getting worse. An estimated 10 million people develop the condition annually,…
Short sellers seem to have many emerging and speculative biotech stocks targeted for termination. Here are eight of them against which short sellers are betting the farm.
People who come into contact with toxic lake water, either by accident or poor judgment, can face extremely severe health consequences.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
Amarin shares dropped on Friday after the firm announced that it received notice from the FDA that delays a pending supplemental new drug application.
Most Americans have never heard of one of the most common forms of skin cancer — one that’s about five times more common than melanoma, and is estimated to kill about twice as many…
DBV Tech shares shot up on Thursday after the company announced the submission of paperwork to the FDA for Viaskin Peanut for the treatment of peanut-allergic children.
Rhythm Pharma shares jumped on Wednesday after the company announced positive results from two of its late-stage obesity clinical trials.